Allergan Reports Availability Of RESTASIS MULTIDOSE 0.05%

(RTTNews) - Allergan plc (AGN) announced the availability of RESTASIS MULTIDOSE, which is the same preservative-free RESTASIS formulation, but now offered in a multidose bottle.

RESTASIS is the first and only prescription medication FDA-approved to help patients with a type of Chronic Dry Eye make more of their own tears. RESTASIS MultiDose is the first and only FDA-approved preservative-free, prescription eye drop in the U.S. to be available in a multidose bottle. RESTASIS was accessible only in single-use vials, since its launch in 2003 until now.

RESTASIS helps increase eyes' natural ability to produce tears, which may be reduced by inflammation due to Chronic Dry Eye. RESTASIS did not increase tear production in patients using anti-inflammatory eye drops or tear duct plugs.

RESTASIS MULTIDOSE is designed with a patented unidirectional valve and air filter technology. The new multi-dose bottle uses less plastic than a package of single-use vials and will be available for the same price.